Evaluation of Neuromuscular Blockade Reversal on Postoperative Outcomes in Cardiovascular Surgery

Ranran "Christina" Xia, PharmD
Divina Tuazon, MD
Nandita Kachru, PhD, MS, BSPharm
Fariedeh Bostan, PharmD
Amaris Fuentes, PharmD, BCPS, BCCC

Background:
Residual neuromuscular blockade can be associated with respiratory complications, prolonged intensive care unit stays, skeletal muscle weakness, and poor recovery. Neostigmine is a reversal agent used to eliminate residual blockade, however, conflicting data exists on its association with respiratory complications, postoperative nausea/vomiting, and cardiac effects.

Methods:
A single center, retrospective chart review was conducted from January 2015 to April 2016. The study included adult patients who received a cardiovascular procedure and a non-depolarizing neuromuscular blocking agent. The primary endpoint was the duration of postoperative mechanical ventilation- defined as the time from end of procedure to time of initial extubation. Pre-specified secondary outcomes included incidence of postoperative atelectasis, incidence of postoperative pneumonia, need for non-invasive positive pressure ventilation after extubation, need for reintubation during hospital stay, discharge disposition, PaO2/FiO2 ratio, total antiemetic doses used up to postoperative day three, hospital length of stay, ICU length of stay, and readmission to ICU during hospitalization.

Results:
Study cohort included in the analysis consisted of 175 patients (neostigmine users n=95; non-users n=80). A difference in duration of mechanical ventilation was noted among neostigmine user and non-user groups (5.23 [IQR 3.93 to 9.33] vs 7.36 [IQR 5.18 to 23], p=0.03). In addition, more neostigmine users met the early extubation benchmark of less than six hours compared to non-users (55 vs. 34 patients, p=0.04). Controlling for all covariates, neostigmine was associated with a 34% (20.4 minute; p=0.007, 95% CI 0.49 to 0.89) reduction in duration of mechanical ventilation. No significant differences were found in regards to secondary endpoints.

Conclusions:
Neostigmine use decreased the duration of post-operative mechanical ventilation in cardiovascular surgery patients. More neostigmine users also met The Society of Thoracic Surgeons' early extubation benchmark less than 6 hours. Neostigmine use was also not found to be associated with increased risk of respiratory complications, postoperative nausea/vomiting, and did not impact length of stay.